Cardiff Oncology, Inc. (TROV) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Royalties	0.4	0.4	0.4	0.2	0.4	0.5	0.4	0.3
Royalties growth	7.5%	-1.9%	49.6%	-35.3%	-25.1%	32.6%	21.8%	11.6%
Costs and expenses:
Research and development	27.1	17.4	11.2	11.2	8.2	7.9	15.0	10.6
Selling, general and administrative	13.2	11.8	8.2	5.8	8.0	14.2	23.0	14.4
Total operating expenses	40.3	29.2	19.5	33.8	17.4	26.1	40.5	25.6
Loss from operations	-39.9	-28.9	-19.1	-16.7	-17.1	-25.6	-40.1	-25.3
Operating margin	-10337.3%	-8037.6%	-5214.8%	-6817.8%	-4507.6%	-5064.4%	-10534.9%	-8079.5%
Interest income, net	1.6	0.3	0.1	0.2	0.2	0.1	0.3
Other income (expense), net	-0.4	0.0	0.0
Total other income (expense), net	1.2	0.6	-0.2
Net loss	-38.7	-28.3	-19.3	-16.4	-16.5	-24.9	-39.2	-27.5
Preferred stock dividend payable on Series A Convertible Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net loss attributable to common stockholders	-38.7	-28.3	-22.6	-16.7	-19.3	-24.9	-39.2	-27.5

Net loss per common share - basic (in dollars per share)	($0.89)	($0.73)	($1.08)	($2.80)	($8.26)	($51.76)	($1.30)	($1.05)
Net loss per common share - diluted (in dollars per share)	($0.89)	($0.73)	($1.08)	($2.80)	($8.26)	($51.76)	($1.37)	($1.21)

Weighted-average shares outstanding - basic (in shares)	43.6	39.0	20.9	6.0	2.3	0.5	30.2	26.2
Weighted-average shares outstanding - diluted (in shares)	43.6	39.0	20.9	6.0	2.3	0.5	30.3	26.5